Usefulness of PET–CT in the assessment of suspected recurrent colorectal carcinoma  by Taha Ali, Tamer F.
The Egyptian Journal of Radiology and Nuclear Medicine (2012) 43, 129–137Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLEUsefulness of PET–CT in the assessment
of suspected recurrent colorectal carcinomaTamer F. Taha AliDepartment of Radiodiagnosis, Faculty of Medicine, Zagazig University, Sharkia, EgyptReceived 31 December 2011; accepted 7 January 2012
Available online 8 February 2012E-
03
M
Pe
N
do
OpKEYWORDS
FDG;
PET/CT;
Colorectal cancer;
Recurrencemail address: tamerfathi2008
78-603X  2012 Egyptian
edicine. Production and host
er review under responsibility
uclear Medicine.
i:10.1016/j.ejrnm.2012.01.001
Production and h
en access under CC BY-NC-ND li@yahoo
Society
ing by El
of Egyp
osting by E
cense.Abstract Purpose: To evaluate the usefulness of PET/CT in detecting recurrent colorectal carci-
noma (CRCR) in patients subsequent to colonic resection or rectal amputation and to compare it
with the PET part of integrated FDG-PET/CT.
Materials and methods: PET/CTs from 32 patients with suspected CRCR were studied. Histology,
clinical follow-up and additional imaging served as the gold standard. The sensitivity, speciﬁcity,
positive and negative predictive values (PPV, NPV), and accuracy of PET as well as integrated
PET/CT were calculated and compared for each of (a) intra-abdominal extra-hepatic recurrences,
(b) extra-abdominal and/or hepatic recurrences, and (c) any form of CRCR.
Results: PPV, sensitivity, NPV, speciﬁcity and accuracy of PET in detecting intra-abdominal extra-
hepatic CRCR were, respectively, 85.7%, 85.7%, 88.9%, 88.9%, and 87.5% compared with 92.9%,
92.9%, 94.5%, 94.5%, and 93.8%, respectively, for PET/CT. The corresponding values for the
detection of extra-abdominal and/or hepatic CRCR were 84.6%, 84.6%, 89.5%, 89.5%, and
87.5% for PET versus 100%, 92.3%, 95%, 100%, and 96.9% for PET/CT. For all forms of recur-
rence, the corresponding values for PET were 80%, 80%, 66.7%, 66.7%, and 75%, respectively,
compared with 94.5%, 90%, 84.6%, 91.7%, and 90.6%, respectively, for PET/CT.
Conclusion: PET/CT enhances the accuracy and speciﬁcity of diagnosis of CRCRa. PET/CT grows
to reach prominent roles for imaging and restaging of patients after colorectal carcinoma resection.
 2012 Egyptian Society of Radiology and Nuclear Medicine. Production and hosting by Elsevier B.V.
Open access under CC BY-NC-ND license..com
of Radiology and Nuclear
sevier B.V.
tian Society of Radiology and
lsevier1. Introduction
rence rates of colorectal cancer (CRC) are still high, with more
prevalence in rectal rather than colon cancer ranging from
7–33% to 1–19%, respectively (1,2). Differentiating the benign
post-therapy changes such as scarring and ﬁbrosis from CRC
recurrence (CRCR) constitutes a diagnostic challenge (3,4)
which is mostly encountered with distal colon and rectal
tumors, where presacral scarring and pelvic changes are
130 T.F. Taha Alicommon. Serum carcinoembryonic antigen (CEA) is a surro-
gate marker for recurrent colorectal cancer with a value of
>5 ng/ml in patients with CRC after treatment suggests recur-
rent disease (5); however, insufﬁcient sensitivity and speciﬁcity
of CEA make it inadequate for surveillance (6).
Conﬁrmation of recurrence of CRC has been evaluated by
physical examinations, colonoscopy and conventional diag-
nostic imaging (CDI) such as US, CT and MRI (5). However,
these traditional methods depend on tumor visualization using
anatomical imaging techniques (7,8), thus, it often fails to de-
ﬁne the extent and resectability of metastatic or recurrent tu-
mors accurately (9,10).
Functional imaging using positron emission tomography
(PET) is a well-established method for the evaluation of
patients with suspected CRCR. It is based on the principal
that metabolically active tumor cells have an increased rate
of glucose consumption owing to an increase in both the rate
of glycolysis and the number of cell membrane glucose trans-
porter molecules, so glucose uptake is increased into the can-
cerous cell. As FDG is an analogue of glucose, its distribution
follows that of glucose-utilizing cells and organs closely, it is
phosphorylated by hexokinase to FDG-6-phosphate and
effectively becomes metabolically trapped, thus, FDG can
be very sensitive in the detection of glucose-avid malignancies.
However, FDG uptake is seen not only in malignant pro-
cesses but also in inﬂammatory and infectious processes
(11–14).
In order to overcome the poor image quality of PET due to
its poor anatomical resolution, a combined PET and CT sys-
tem, an integrated PET/CT scanner, were developed in 1998
and are now widely used in oncology patients. Integration of
PET and CT can yield accurate localization of a lesion on
FDG-PET within the CT anatomical mapping (15–18).
The aim of the present study was to evaluate the usefulness
of FDG-PET/CT in detecting recurrence of colorectal carci-
noma in patients subsequent to colonic resection or rectal
amputation and to compare it with the PET part of integrated
FDG-PET/CT.Table 1 Final diagnosis of all patients.
Form of recurrence No.
Present Absent
Intra-abdominal extra-hepatic recurrence 14 18
Extra-abdominal/hepatic recurrence 13 19
Any form of recurrence 20 122. Materials and methods
2.1. Patients
Thirty-two patients, 21 men and 11 women with a mean age of
63 years (range 42–76 years) with previous colonic resection or
rectal amputation for CRC were included in this study. They
were referred for PET/CT assessment of suspected recurrent
CRC on routine follow-up imaging and/or elevated CEA.
The study protocol was approved by our institutional review
board and informed consent was obtained from all patients.
All patients fasted for at least 5 h to lower insulin and blood
sugar levels. Blood glucose levels were in its normal range prior
to 18-FDG injection. PET/CT was done 60 min after I.V.
administration of approximately 5 MBq/kg body weight of
FDG (up to 550 MBq).
2.2. The PET/CT technique
The whole body was scanned using a PET/CT scanner (Bio-
graph, Siemens) system with 64-slice multi-detector CT. Scanswere acquired from skull base to mid-thigh level. The CT scan
component was obtained before the PET component by using
the following parameters: 80–100 mA, 140 kV, 5 mm collima-
tion, 0.5 s rotation time; and pitch = 0.984. Patients were posi-
tioned supine with arms up whenever tolerated to avoid
artifact, they were allowed to maintain normal respiration dur-
ing scanning. The I.V. contrast medium (2 ml/kg, 5 ml/s of
nonionic contrast media) was administered immediately before
CT (in 23 patients). Reconstructed section thickness was
1.2 mm. Subsequently, PET data were acquired in at 5–7 bed
positions for 5 min per each bed position. Data obtained from
the CT acquisition were used for attenuation correction of
18FDG-PET emission data. 18FDG-PET images were recon-
structed with a 4.5 mm thickness. 18FDG-PET, CT and fused
18FDG-PET/CT images were reviewed on the dedicated
workstation.
2.3. Image Interpretation
Axial sections and multiplanar reconstructions of CT, PET
and fused PET/CT images were analyzed for recurrent colorec-
tal carcinoma. Lung and bone windows were systematically re-
viewed. Abnormal FDG uptake was deﬁned as focal increased
activity higher than the background activity of soft tissues. The
evaluation of each focal radiotracer uptake was qualitative and
quantitative (the standard maximum uptake value (SUV max).
CT was used to localize FDG uptake as either (a)
intra-abdominal extra-hepatic or (b) extra-abdominal and/or
hepatic, as well as to evaluate morphological changes, such
as colonic wall thickening (>3 mm), soft tissue mass, lym-
phadenopathy (>15 mm) in the abdomen and (>10 mm) in
the pelvis, osseous changes, any nodules in the liver, lung, or
other organs.
2.4. Standard of reference
In all patients, the gold standard was biopsy, surgery, or
clinical and radiological follow-up for at least 6 months. The
histological conﬁrmations were obtained within 4 weeks of
FDG-PET/CT (n= 21), while 11 patients without histological
conﬁrmation were monitored for a mean period of 7 months
(6–8.5 months).
2.5. Statistical analysis
The sensitivity, speciﬁcity, positive predictive value (PPV),
negative predictive value (NPV), and accuracy of PET as well
as integrated PET/CT report were calculated and compared
together. McNemar and T test were used to compare results.
Statistical signiﬁcance was set at p< 0.05.
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Thirty-two patients were enrolled in our study; they were
classiﬁed according to the site of recurrence as following
(Table 1):
(i) Intra-abdominal extra-hepatic recurrence.
(ii) Extra-abdominal and/or hepatic recurrence.
(iii) Any form of recurrence.
3.1. Intra-abdominal extra-hepatic recurrence (Figs. 1, 2, and 6)
Of 14 patients with ﬁnally proven intra-abdominal extra-hepa-
tic recurrence, 12 showed focal FDG increased uptake (true
positive) while two cases did not show any pathological focal
FDG uptake (false negative). These false negative cases in-
cluded a patient with microscopic local recurrence, which
had no detected pathology at CT studies while the other false
negative case had para-aortic lymph node recurrence that was
detected at CT (Fig. 5).
FDG-PET/CT correctly diagnosed 13 of these 14 patients
(true positive) while FDG-PET/CT had one false negative case
due to microscopic recurrences that was discovered by colono-
scopic biopsy.
Of 18 patients who were ﬁnally proved to have no intra-
abdominal extra-hepatic recurrence, 16 patients showed no
abnormal focal uptake of FDG (true negative) while false
positive uptake was shown in two patients as following:Fig. 1 Local recurrence of colonic carcinoma with avid FDG uptakone with post-operative collection that showed typical CT
signs. The other case was due to inﬂammatory colonic
changes that were conﬁrmed histo-pathologically to be be-
nign changes.
FDG-PET/CT was truly negative in 17 of these patients
while one case was false positive due to inﬂammatory changes
in the colon.
3.2. Hepatic/extra-abdominal recurrence (Fig. 3)
Thirteen patients were ﬁnally proven to have extra-abdominal
and/or hepatic recurrences. These recurrences were hepatic
only (n= 4), extra-abdominal only (n= 4) while deposits in-
volved both in ﬁve patients (Table 2).
Eleven of these 13 patients showed focal pathological FDG
uptake (true positive) while two patients were false negative
(no focal FDG uptake), CT showed one of them to have small
metastatic lung nodule, while the second case was normal at
CT study.
Twelve of these 13 patients were correctly diagnosed by
integrated FDG-PET/CT (true positive). However, a false neg-
ative case with miliary liver deposits showed no focal lesions at
CT study or abnormal focal uptake of FDG but follow-up
showed serial increase in CEA with the detection of small liver
deposits.
Of the 19 patients without extra-abdominal and/or hepatic
CRCR at ﬁnal diagnosis, 17 patients showed no focal in-
creased FDG uptake (true negative). While the remaining
two cases showed FDG focal uptake (false positive), theye. (a) PET, (b) CT, (c) axial PET/CT, and (d) coronal PET/CT.
Fig. 2 Large loco-regional and nodal CRCR with intense radiotracer uptake. (a and b) PET, (c and d) CT, (e and f) axial PET/CT, and
(g) coronal PET/CT.
132 T.F. Taha Aliincluded liver abscess (n= 1), and bronchopneumonia (n= 1)
(Fig. 4).
On the other hand, FDG-PET/CT correctly diagnosed
these 19 patients with no false positive cases.
3.3. Any form of recurrence
At ﬁnal diagnosis, 20 patients had any form of recurrence (of
them, seven patients had combined intra-abdominal and extra-
abdominal/hepatic recurrence) while 12 patients were recur-
rence free.
Of the 20 patients with ﬁnally proven recurrence of
any form, FDG focal pathological uptake was observedin 16 patients (true positive) while four patients showed
no focal FDG uptake (false negative), on the other hand
the FDG-PET/CT correctly discovered 18 of these 20
patients (true positive). However, a false negative result
was encountered in two cases, which did not show any
abnormal focal uptake of FDG or any pathology at CT
study.
Of the 12 recurrence free patients, eight patients showed no
focal FDG uptake (true negative) while four patients showed
false positive result.
At PET/CT, 11 of these 12 patients were correctly diag-
nosed as recurrence free (true negative) while we had one false
positive patient.
Fig. 3 CRCR with metabolically active disseminated deposits (mediastinal LN, left lung, liver, right adrenal and osseous). Bilateral
pleural effusion and thickening as well as IVC thrombosis were noted. (a–c) PET, (d–g) CT, (h–j) axial PET/CT, and (k) coronal
PET/CT.
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True and false positive as well as true and false negative results
of PET and PET/CT in each form of recurrence were recorded
(Table 3). PPV, sensitivity, NPV, speciﬁcity and accuracy of
PET in detecting intra-abdominal extra-hepatic CRCR were,
respectively, 85.7%, 85.7%, 88.9%, 88.9%, and 87.5% com-
pared with 92.9%, 92.9%, 94.5%, 94.5%, and 93.8%, respec-
tively, for PET/CT. The corresponding values for the detection
of extra-abdominal and/or hepatic CRCR were 84.6%, 84.6%,
89.5%, 89.5%, and 87.5% for PET versus 100%, 92.3%, 95%,
100%, and 96.9% for PET/CT.
For any forms of recurrence, the corresponding values for
PET were 80%, 80%, 66.7%, 66.7%, and 75%, respectively,
compared with 94.5%, 90%, 84.6%, 91.7%, and 90.6%, respec-
tively, for PET/CT. The accuracy of PET/CT showed a trendtoward better performance than PET (p= 0.07), while speciﬁc-
ity was higher for PET/CT in comparison to PET alone but still
not quite signiﬁcant. On the other hand, the difference between
the sensitivity of PET/CT and PET alone was not signiﬁcant
(Table 4).
4. Discussion
Early detection of recurrent colorectal carcinoma has become
more crucial as the treatment options have improved signiﬁ-
cantly (19). Anatomic imaging can detect pathologic processes
only after they reach a detectable size, become contour
deforming, or have abnormal enhancement after intravenous
contrast (20,21). CT may have signiﬁcant difﬁculties in differ-
entiating tumor recurrence from benign post-operative and/or
post-radiotherapy ﬁbrosis. Accuracy of T1- and T2-weighted
Fig. 4 False FDG uptake at PET (a), shown at CT. (b)
Mediastinal window, (c) lung window, and (d) PET/CT as left
pulmonary consolidated segment.
Fig. 5 Nodal recurrence with no abnormal FDG uptake (false
negative) at PET (a) while obvious at CT (b), and PET/CT (c).
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ultrasound may also have a role to play, but imaging protocols
need to be standardized (11).
Visualization of metabolism using 18F-FDG-PET is a valu-
able tool (8) that may detect tumor sites throughout the body
with high contrast resolution. Many works showed that thePET provides excellent functional information, which is often
the earliest sign of tumor recurrence and which may be present
before morphological changes are detectable. Many literature
(11,22–26) reports that the FDG-PET accuracy in detecting
CRC recurrence is higher than that of CT. In addition, many
studies (8,11,20,26) showed the high sensitivity of PET in pa-
tients with colorectal carcinoma.
However, exact localization and demarcation of lesions
with PET are affected by its relatively low spatial resolution,
and lack of anatomical reference so integration of PET and
CT can provide synergistic beneﬁt and may deliver the stron-
gest diagnostic tool that has high quality combined anatomical
and metabolic information with increased accuracy (14,27–
29). This was conﬁrmed in many studies which showed the
higher accuracy of PET/CT in comparison to PET alone in
detection of recurrent CRC (88% versus 71% (30), 89% versus
78% (29), 90% versus 75% (4)). Even-Sapir et al. (26) also
showed the additional value of PET–CT in the detection of
pelvic recurrence after the surgical removal of rectal cancer.
Engledow et al. (14) in another study demonstrated improved
accuracy of PET/CT over PET alone in both staging and
restaging in CRC thus positively inﬂuenced the surgical
management.
This is also conﬁrmed in our study, as the accuracy of PET/
CT was higher than that of FDG-PET alone. It was, respec-
tively, 93.8% versus 87.5% for intra-abdominal extra-hepatic,
96.9% versus 87.5% for extra-abdominal/hepatic while it was
90.6% versus 75% for detection of any metastases in the entire
population. We also demonstrated the higher speciﬁcity of
PET/CT in comparison to FDG-PET alone; it was, respec-
tively, 94.5% versus 88.9% for intra-abdominal extra-hepatic,
100% versus 89.5% for extra-abdominal/hepatic while it
showed a trend toward better performance than PET
(p= 0.07) in the detection of any form of recurrence, it was
91.7 versus 66.7%, respectively.
Several studies (31–34) showed the high sensitivity of 18F-
FDG-PET/CT to conﬁrm and localize disease recurrence with
a negative predictive value near 100%. In the study carried out
by Kyoto et al. (5) the sensitivity of PET/CT to detect CRC
recurrence was 93%.
In current study, the sensitivity of FDG-PET/CT was not
signiﬁcantly higher than that of FDG-PET. This agrees with
the result of Votrubova et al. (4) who found that despite the
ability of PET/CT to detect small lung and/or liver metastases
(in 4 of their patients), there was non-signiﬁcant increase in
sensitivity between FDG-PET (80%) and FDG-PET/CT
(89%) and they attributed this to predominant dependency
of FDG-PET/CT sensitivity on FDG uptake. This is sup-
ported by the results of Arulampalam et al. (11), who reported
that FDG-PET was more sensitive (100%) than CT (75%) for
staging local recurrence. And this matches also with Wiering
et al. (35) study which showed that FDG-PET/CT has superior
sensitivity in respect to CT in the detection of colorectal metas-
tases, and the pooled sensitivity and speciﬁcity were, respec-
tively, 88% and 96.1% for hepatic disease and 91.5% and
95.4% for extra-hepatic disease.
Many literatures reported that FDG-PET/CT has superior
sensitivity compared to CT in the detection of colorectal liver
metastases and in revealing extra-hepatic disease (especially
metastases to peritoneum, mesentery, and lymph nodes) (36).
As the liver is the most common site for CRC metastasis
(37), it was the focus of many studies which showed the higher
Table 2 Site of hepatic/extra-abdominal recurrence.
Site No.
Hepatic deposits only 4
Extra-abdominal only 4
Hepatic and extra-abdominal 5
Total 13
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hepatic metastases 96% versus 88% (38) and 97% versus
87.9% (39), respectively. Furthermore, some authors reported
that solitary liver metastasis patients who underwent FDG-
PET/CT before hepatic resection, have an overall 3-years sur-
vival of 77%, higher than those in the previously published ser-
ies selected without FDG-PET (40,41). A recent meta-analysis
(42) demonstrated the sensitivities of CT, MR, and FDG-PETFig. 6 Recto-sigmoid recurrence with hypermetabolism and avid FDG
PET, (b) CT, (c) axial, (d) coronal, and (e) sagittal PET/CT.
Table 3 Results of PET and PET–CT compared to ﬁnal diagnosis.
Intra-abdominal extra-hepatic recurrence Extra-a
FDG uptake PET/CT FDG u
True positive 12 13 11
False negative 2 1 2
True negative 16 17 17
False positive 2 1 2for detecting hepatic metastases from CRC to be 83.6%,
88.2%, and 94.1%, respectively.
In the current study, FDG-PET/CT showed increased accu-
racy compared to FDG uptake alone in the diagnosis of extra-
abdominal and/or hepatic recurrence; 96.9% versus 87.5%,
respectively. Our result agrees with the study of Votrubova
et al. (4) who attributed this increase to higher frequency of
false positive ﬁndings on FDG-PET due to inﬂammatory lung
changes and liver biopsy channel, which can demonstrate typ-
ical CT picture.
We encountered a false negative case at FDG (no focal up-
take), which was correctly diagnosed at CT as small metastatic
pulmonary nodule, this may be due to limited spatial resolu-
tion of PET, thus a negative PET scan cannot exclude pulmon-
ary metastases with certainty, while a positive FDG-PET will
generally conﬁrm suspicious abnormalities detected on the
CT images (43).uptake. Cirrhotic liver with hepato-splenomegaly were noted. (a)
bdominal and/or hepatic recurrence Any form of recurrence
ptake PET/CT FDG uptake PET/CT
12 16 18
1 4 2
19 8 11
0 4 1
Table 4 Summary of statistical analysis of PET and PET–CT results.
Value Intra-abdominal Extra-abdominal/hepatic Any form
FDG PET/CT FDG PET/CT FDG PET/CT
Positive predictive value (%) 85.7 92.9 84.6 100 80 94.5
Sensitivity (%) 85.7 92.9 84.6 92.3 80 90
Negative predictive value (%) 88.9 94.5 89.5 95 66.7 84.6
Speciﬁcity (%) 88.9 94.5 89.5 100 66.7 91.7
Accuracy (%) 87.5 93.8 87.5 96.9 75 90.6
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rect dependency on its size, and hence it can determine the
presence or absence of malignancy even in non-enlarged node
(44,45). However, PET may be false negative in small lymph
nodes and some cystic or mucinous nodal metastases. On the
other hand, it may be false positive due to inﬂammation,
and so the FDG-PET images cannot be entirely relied upon
to exclude lymph node metastases in the setting of CRC (3).
In our series, we had a false negative patient with para-aortic
LN at FDG-PET that was detected at CT.
Many studies suggest that PET–CT is both sensitive and
speciﬁc for diagnosing malignant bone lesions (46,47). Focal
FDG uptake can be used as a guide to examine the correspond-
ing CT for concordant abnormalities such as a soft tissue mass
or bone erosion. Interpretation of PET–CT should be corre-
lated with the patient’s clinical status as some imaging features
overlap between abscess and cystic metastatic disease (3). We
agree with this opinion as in our series we had ﬁve patients with
bone metastases, all were correctly detected at PET–CT.
False negative or positive results represents a problem espe-
cially at FDG-PET study, false positive results may be due to
physiological, infective or inﬂammatory processes. Physiologi-
cal uptake by the bowel can sometimes mimic tumoral uptake
(48). Inﬂammatory uptake of hilar and mediastinal lymph
nodes is more frequent among patients with lung complications
(49). Some benign or inﬂammatory liver lesions can also have
focal FDG uptake (50). In current study, we had four false po-
sitive cases at PET, while this number was reduced to one case
at PET/CT. This enhances the recommendation of O’Connor
et al. (3) who stressed on the value of careful analysis of CT
images of anastomotic and presacral regions especially in cases
of ﬁstulous and sinus tracts and abscesses which typically show
intense abnormal FDG tracer uptake. This also agrees with Ka-
mel et al. (20) who attributed the improved overall accuracy of
the combined PET/CT mainly to improved speciﬁcity that re-
sulted from the decreased number of false positive PET cases.
Kyoto et al. (5) explained some false negative results by the
effect of received adjuvant chemotherapy, which lower the
FDG uptake below diagnostic levels. Therefore, they recom-
mend that serial increase in CEA during follow-up might be
an important indicator of recurrent disease even when FDG-
PET/CT ﬁndings are negative. In current study, we had overall
total of four false negative cases in the entire population at PET
while at PET/CT there were only two false negative patients.
CEAcontinued to increase in all PET/CT false negative patients.
We agree with the opinion of several earlier authors
(4,14,36) in that PET/CT imaging has the potential to become
the preferred imaging modality in CRCR because it identiﬁes
and localizes the disease in one setting and can guide diagnos-
tic or therapeutic interventions. Our study supports the routineuse of PET/CT in the imaging algorithm for patients with sus-
pected CRC.
In the current study we had some limitations, ﬁrst is the po-
tential of PET–CT for false positive results due to the presence
of inﬂammatory reaction, the potential of PET/CT for false
negative results is another limitation as adjuvant chemother-
apy may interfere with FDG uptake. PET/CT has limitations
in distinguishing the wall layers of the colon. Our study is also
limited by the relatively low rate of histological conﬁrmation
of diagnosis (n= 21). High radiation dose is also another dis-
advantage of PET/CT study.
Future developments of PET–CT techniques are expected
with the establishment of newer isotopes that are more speciﬁc
as well as to reduce radiation dose and improvement of spatial
resolution.
In conclusion, integrated FDG-PET/CT enhances the accu-
racy and speciﬁcity of diagnosis of recurrent colorectal carci-
noma; it has a higher NPV and PPV than FDG-PET alone.
FDG-PET/CT is reaching prominent roles sufﬁciently to be-
come a routine non-invasive tool for imaging and restaging
of patients after CRC resection.References
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